A Nature Communications report explains why some Merkel cell carcinoma patients treated with immunotherapy see their cancers shrink at first but then come back.
Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma